Loading... Please wait...
Contact Us
Would you like more
information on this report
Please contact us today at +44(0)20.7665.9240
or +1 212.220.0880
or write to us.

Melanoma: Update Bulletin #2 [May 2018]

Product Code:
Publication Date:
May 2018

This edition presents key opinion leader (KOL) views on recent developments in the malignant melanoma (MM) market. Topics covered include: Merck & Co. and Incyte’s announcement of the Phase III ECHO-301/KEYNOTE-252 study with pembrolizumab (Keytruda) and the IDO1 inhibitor epacadostat; NewLink Genetics announcing that it will not proceed to the randomisation portion of its Phase I/II Indigo301 study for its putative IDO inhibitor indoximod; Dynavax Technologies presentation of interim data from its Phase Ib/II MEL-01/KEYNOTE-184 study evaluating SD-101, an intratumoural toll-like receptor (TLR) 9 agonist, in combination with Keytruda and Idera Pharmaceuticals commencement of the Phase III ILLUMINATE 301 study evaluating tilsotolimod (IMO-2125), an endosomal TLR9 agonist, with ipilimumab (Yervoy; BMS) compared to Yervoy alone in MM patients who have not responded to anti-PD1 therapy.

Business Questions:

  • What is the experts’ reaction to the failure of the ECHO-301 study for Incyte’s epacadostat?
  • How will epacadostat data impact the development of IDO1 inhibitors? Is this the end of the road for IDOs?
  • What will be NewLink Genetics’ strategy for development of indoximod?
  • How do KOLs view the potential of TLR9 agonists in the melanoma space?
  • Will Dynavax Technologies’ SD-101 be able to replicate its earlier promise in a larger Phase III study? What do KOLs think?
  • Will SD-101 combination with Keytruda find a place in the treatment algorithm?
  • How do KOLs view the progress of ILLUMINATE 301 study and will it deliver Idera’s novel TLR-9 agonist, tilsotolimod?
  • How do KOLs rate Idera’s tilsotolimod against Dynavax Technologies’ SD-101? Which one stands out?


All Contents Copyright © 2020 Doctor's Guide Publishing Limited All Rights Reserved